Innate Pharma S.A. (OTCMKTS:IPHYF) Logo

The stock of INNATE PHARMA MARSEILLE SHARES NOM CAT – (OTCMKTS:IPHYF) registered a decrease of 0.65% in short interest. IPHYF’s total short interest was 338,100 shares in September as published by FINRA. Its down 0.65% from 340,300 shares, reported previously. With 1,400 shares average volume, it will take short sellers 242 days to cover their IPHYF’s short positions.

It closed at $6.73 lastly. It is down 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Innate Pharma S.A., a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company has market cap of $439.21 million. The firm offers Lirilumab , a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas. It currently has negative earnings. It is also involved in developing IPH4301, a humanized anti-MICA/B therapeutic antibody to treat oncology; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH33, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.

More notable recent Innate Pharma S.A. (OTCMKTS:IPHYF) news were published by: which released: “Bristol-Myers Squibb And Innate Pharma: Innovation Is Never A Single Event – Seeking Alpha” on March 06, 2017, also with their article: “Innate Pharma Poised To Fill A Gap In Cancer Immunotherapy – Seeking Alpha” published on February 26, 2019, published: “Innate Pharma 2016 Q4 – Results – Earnings Call Slides – Seeking Alpha” on March 07, 2017. More interesting news about Innate Pharma S.A. (OTCMKTS:IPHYF) were released by: and their article: “Who Heard About This Biotech? – Seeking Alpha” published on October 17, 2016 as well as‘s news article titled: “Innate Pharma provides corporate update – Seeking Alpha” with publication date: March 20, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.